Promptly Health links 70 million clinical lives

Promptly Health, the Porto-founded federated health-data company, has integrated Hapvida NotreDame Intermédica into its network, adding 16 million Brazilian beneficiaries and bringing the total population covered by its platform to more than 70 million people across Europe and Brazil.

The deal was confirmed on 25 June 2026. Financial terms were not disclosed. Hapvida joins without upfront capital investment, as Promptly's network model allows data partners to onboard at zero cost and generate revenue by participating in sponsored studies and feasibility queries.

Promptly, founded in 2017, operates a federated real-world evidence platform that lets hospitals and health systems share clinical knowledge without physically transferring patient data. Researchers and authorised organisations query the network and receive results without the underlying records ever leaving the institution that holds them. The platform competes with TriNetX, Aetion, and Rhino Federated Computing in the real-world evidence infrastructure market. TriNetX's LIVE network has crossed 300 million patients across 240 healthcare organisations, a scale advantage Promptly has not yet matched in aggregate. What Promptly has built instead is regulatory architecture: its platform is designed from the ground up to fulfil the functional and governance requirements of the EU's incoming European Health Data Space regulation, meaning US-headquartered rivals face that framework as an external constraint while Promptly treats it as a native product specification.

The EHDS Regulation was published on 5 March 2025 and entered into force on 26 March 2025. Secondary-use rules for most data categories activate in March 2029, opening a four-year window in which network scale and EHDS-readiness are the decisive commercial variables. Promptly is already embedded in national preparation: since 2024 it has helped build Portugal's National Health Data Lake and has begun establishing the infrastructure for Portugal's Health Data Access Body role, with Portugal becoming the first EU member state to publish a national dataset in the acceptance environment of the HealthData@EU Central Platform.

The Hapvida node changes the competitive geometry in two ways. First, it adds epidemiological diversity that European networks structurally cannot replicate: Brazilian health data sits outside mandatory EHDS scope, meaning it enriches the network without triggering the EU compliance obligations that apply to European nodes. Second, Hapvida is not a small anchor. The group is the largest integrated health company in Latin America, with more than 73,000 employees, 86 hospitals, 78 emergency units, 363 medical clinics, and 305 diagnostic centres covering all five regions of Brazil.

"With 16 million beneficiaries and a network that covers every region of Brazil, Hapvida brings a depth of real-world clinical knowledge that has, to a large extent, been inaccessible to the global research community." — Pedro Ramos, CEO, Promptly Health.

"Brazil has an extraordinary wealth of clinical data that is still, to a large extent, invisible to the global research community. This partnership with Promptly Health gives us the tools to structure and curate these data, creating a bridge between the day-to-day reality of our hospitals and the evidence that researchers and innovators need." — Rodrigo Sardenberg, Director, Hapvida NotreDame Intermédica.

Promptly's existing network connects approximately 400 hospitals and healthcare organisations across Portugal, Spain, France, Germany, and the United Kingdom. Clients on the research demand side include commercial, medical, and health economics teams at Roche, Novartis, and Johnson & Johnson. The company also holds a technology partnership with Datavant, integrating Datavant's tokenisation layer with Promptly's secure access infrastructure to convert routine medical records into research-ready data assets.

The Hapvida integration positions Promptly as the default cross-Atlantic infrastructure layer for pharma real-world data studies at the precise moment European life-science companies are being forced to reorient their data strategies around EHDS secondary-use requirements. A company with disclosed funding of under €1 million has now built a network connecting more clinical lives than most national health systems can count, by making regulatory compliance the product rather than the constraint.